Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,128 public posts
Filter results
Details of the VISION trial of Lu-177-PSMA-617 presented at ASCO
approval, this could become a novel treatment approach June 6, 2021—177Lutetium-labeled prostate-specific membrane antigen (PSMA) resulted in improvements in both progression-free survival (PFS) and overall survival (OS) when given in combination with standard of care in patients with metastatic
castration
-resistant
approval, this could become a novel treatment approach June 6, 2021—177Lutetium-labeled prostate-specific membrane antigen (PSMA) resulted in improvements in both progression-free survival (PFS) and overall survival (OS) when given in combination with standard of care in patients with metastatic
castration
-resistant
Tall_Allen
in
Advanced Prostate Cancer
3 years ago
Optimal Chemo-Hormonal Sequencing for MCRPC Maybe Taxotere - Zytiga - Jevtana - Xtandi
In a retrospective study presented at the Society for Urologic Oncology 2020 meeting, researchers from the Mayo Clinic reported a small 112 patient cohort with metastatic
castration
-resistant prostate cancer (mCRPC).
In a retrospective study presented at the Society for Urologic Oncology 2020 meeting, researchers from the Mayo Clinic reported a small 112 patient cohort with metastatic
castration
-resistant prostate cancer (mCRPC).
JoelT
in
Fight Prostate Cancer
3 years ago
Xofigo 2.0
It's been almost 8 years since the FDA approved Xofigo for symptomatic, bone metastatic,
castration
-resistant PC, with no visceral metastases.
It's been almost 8 years since the FDA approved Xofigo for symptomatic, bone metastatic,
castration
-resistant PC, with no visceral metastases.
Tall_Allen
in
Advanced Prostate Cancer
3 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Lifestyle - diet, exercise, stress reduction sure seems to make a difference
The next step would be hormonal therapy, which is chemical or surgical
castration
, but that has a list of side effects, including loss of libido, sexual function, strength, and vitality.
The next step would be hormonal therapy, which is chemical or surgical
castration
, but that has a list of side effects, including loss of libido, sexual function, strength, and vitality.
wstein25
in
Active Surveillance - Prostate Cancer
3 years ago
Parp Inhibitors - what are the risks?
Back in 2017 there was a paper from Duke, NC: "
Acute Myeloid Leukemia After Olaparib Treatment in Metastatic
-Resistant Prostate Cancer" "Poly(adenosine diphosphate-ribose) polymerase (PARP) in- hibitors exploit defects in DNA repair to induce tumor-selective cytotoxicity and are in
Back in 2017 there was a paper from Duke, NC: "
Acute Myeloid Leukemia After Olaparib Treatment in Metastatic
-Resistant Prostate Cancer" "Poly(adenosine diphosphate-ribose) polymerase (PARP) in- hibitors exploit defects in DNA repair to induce tumor-selective cytotoxicity and are in
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Cytoreductive surgery for Oligometastatic PCa.
.), while there were no significant difference in progresses to
castration
-resistant prostate cancer" "The cytoreductive surgery held advantages in overall survival, cancer-specific survival, and progression-free survival.
.), while there were no significant difference in progresses to
castration
-resistant prostate cancer" "The cytoreductive surgery held advantages in overall survival, cancer-specific survival, and progression-free survival.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
PSA rising, won't be able to escape ADT. Any tips for brain-fog and depression handling?
The oncologist absolutely wants me to try ADT once more to see if I am
castration
resistant or not (I've never reached a PSA below 1.9 on Lupron and my PSA only climbed on Casodex).
The oncologist absolutely wants me to try ADT once more to see if I am
castration
resistant or not (I've never reached a PSA below 1.9 on Lupron and my PSA only climbed on Casodex).
Mascouche
in
Advanced Prostate Cancer
3 years ago
FT-7075, New Phase 1 Clinical Trial
Here's the company's web page for the therapy... https://www.formatherapeutics.com/programs/metastatic-
castration
-resistant-prostate-cancer/ and the US government info at https://clinicaltrials.gov/ct2/show/NCT04575766?term=FT-7051&draw=2&rank=1 .
Here's the company's web page for the therapy... https://www.formatherapeutics.com/programs/metastatic-
castration
-resistant-prostate-cancer/ and the US government info at https://clinicaltrials.gov/ct2/show/NCT04575766?term=FT-7051&draw=2&rank=1 .
StePeteMN
in
Advanced Prostate Cancer
3 years ago
Bipolar Androgen Therapy vs Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Bipolar androgen therapy (BAT), defined as rapid cycling between high and low serum testosterone, disrupts this adaptive regulation in
castration
-resistant PCa (CRPC).
Bipolar androgen therapy (BAT), defined as rapid cycling between high and low serum testosterone, disrupts this adaptive regulation in
castration
-resistant PCa (CRPC).
Balsam01
in
Advanced Prostate Cancer
3 years ago
Radioligand (LU177) shows benefit over chemotherapy (Cabazitaxel) in prostate cancer
https://wchh.onlinelibrary.wiley.com/do/10.1002/tre.0030031 PSMA (prostate-specific membrane antigen) -targeted radiopharmaceutical therapy could be more effective and better tolerated than current chemotherapy in patients with metastatic
castration
-resistant prostate cancer (mCRPC), according to a recent
https://wchh.onlinelibrary.wiley.com/do/10.1002/tre.0030031 PSMA (prostate-specific membrane antigen) -targeted radiopharmaceutical therapy could be more effective and better tolerated than current chemotherapy in patients with metastatic
castration
-resistant prostate cancer (mCRPC), according to a recent
HopingForTheBest1
in
Advanced Prostate Cancer
3 years ago
Paper of interest to MHSPc
I have not read the full paper yet but this looks interesting from the abstract Comparison of Systemic Treatments for Metastatic
Castration
-Sensitive Prostate Cancer JAMA Oncol; 2021 Jan 14; EPub Ahead of Print; L Wang, CJ Paller, H Hong, et al
I have not read the full paper yet but this looks interesting from the abstract Comparison of Systemic Treatments for Metastatic
Castration
-Sensitive Prostate Cancer JAMA Oncol; 2021 Jan 14; EPub Ahead of Print; L Wang, CJ Paller, H Hong, et al
Proflac
in
Advanced Prostate Cancer
3 years ago
Does castration effectively knock down the PSA?
I want to get
castration
but having a problem getting DR to perform procedure without going through every alternative. I don't really want to take the shots. Anyone relate?
I want to get
castration
but having a problem getting DR to perform procedure without going through every alternative. I don't really want to take the shots. Anyone relate?
Barryctlc
in
Advanced Prostate Cancer
4 years ago
Vaccine Candidates of Interest--- pTVG-HP DNA Vaccine and pTVG-AR DNA vaccine-- Brothers with Different Targets
In the conclusion in the trial, the following was stated, "Association between immunity and PPFS suggests that treatment may delay the time to
castration
resistance, consistent with preclinical findings, and will be prospectively evaluated in future trials. see below: https://clincancerres.aacrjournals.org
In the conclusion in the trial, the following was stated, "Association between immunity and PPFS suggests that treatment may delay the time to
castration
resistance, consistent with preclinical findings, and will be prospectively evaluated in future trials. see below: https://clincancerres.aacrjournals.org
NPfisherman
in
Fight Prostate Cancer
3 years ago
Androgen Cycling Shows Promise in Castration-Resistant Prostate Cancer
"Following disease progression with abiraterone (Zytiga), treatment with bipolar androgen therapy (BAT) or enzalutamide (Xtandi) led to a median progression-free survival (PFS) of 5.7 months (clinical or radiographic progression). A similar proportion of patients in each treatment arm had at least
"Following disease progression with abiraterone (Zytiga), treatment with bipolar androgen therapy (BAT) or enzalutamide (Xtandi) led to a median progression-free survival (PFS) of 5.7 months (clinical or radiographic progression). A similar proportion of patients in each treatment arm had at least
snoraste
in
Advanced Prostate Cancer
3 years ago
Recent study on Flubendazole for castration resistant PCa - Another repurposed drug
P53 protein in
Castration
-resistant Prostate Cancer cells.
P53 protein in
Castration
-resistant Prostate Cancer cells.
Graham49
in
Advanced Prostate Cancer
4 years ago
FDA has approved Relugolix (Orgovyx) for advanced PCa.
Of note, relugolix did not improve
castration
resistance–free survival through 48 weeks versus leuprolide acetate in patients with metastatic prostate cancer.2 Overall, 74% of men who received relugolix were
castration
-resistance free through 48 weeks versus 75% of patients who received leuprolide (HR
Of note, relugolix did not improve
castration
resistance–free survival through 48 weeks versus leuprolide acetate in patients with metastatic prostate cancer.2 Overall, 74% of men who received relugolix were
castration
-resistance free through 48 weeks versus 75% of patients who received leuprolide (HR
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Starting xgeva next month
Now
castration
resistant moving on to the more expensive and stronger drugs. I also read in trials that xgeva kills cancer cells by red flagging the cells so the immune system can kill them.
Now
castration
resistant moving on to the more expensive and stronger drugs. I also read in trials that xgeva kills cancer cells by red flagging the cells so the immune system can kill them.
Muffin2019
in
Advanced Prostate Cancer
4 years ago
PSA
My T must not be at the
castration
level cause I still peek at the ladies.
My T must not be at the
castration
level cause I still peek at the ladies.
Howard53545
in
Advanced Prostate Cancer
4 years ago
BRCA, ATM, CHEK news: ASCO GU 2021: Talazoparib Demonstrates Durable Antitumor Activity in Metastatic Castration-Resistant Prostate Cancer
For the multinational phase II TALAPRO-1 trial, 128 patients with progressive metastatic
castration
-resistant prostate cancer were enrolled between June 4, 2017 and March 20, 2020.
For the multinational phase II TALAPRO-1 trial, 128 patients with progressive metastatic
castration
-resistant prostate cancer were enrolled between June 4, 2017 and March 20, 2020.
Balsam01
in
Advanced Prostate Cancer
3 years ago
Adaptive Theory for PCa - Part Two: Frameworks for treatment models, Eco-evolutionary Stability in mCRPCa, & AR is very adaptive
However,
castration
-resistant cells may be selected by the treatment and accumulate. Treatment with AR antagonists and other therapeutic drugs, including chemotherapy and radiation, might select for drug resistant PCa cells leading to a more aggressive tumor (such as NEPC).
However,
castration
-resistant cells may be selected by the treatment and accumulate. Treatment with AR antagonists and other therapeutic drugs, including chemotherapy and radiation, might select for drug resistant PCa cells leading to a more aggressive tumor (such as NEPC).
cujoe
in
Fight Prostate Cancer
3 years ago
1
...
23
24
25
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1005 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest